graphic
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 


FORM 8-K
 

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act Of 1934
 
Date of Report (Date of earliest event reported): June 28, 2023
 

 
ATI PHYSICAL THERAPY, INC.
(Exact name of registrant as specified in its charter)
 


 Delaware
  001-39439
  85-1408039
 (State or other jurisdiction of incorporation)
 (Commission File Number)
 (IRS Employer Identification No.)

 790 Remington Boulevard
   
     
  Bolingbrook, Illinois
 
 60440
 (Address of principal executive offices)
 
 (Zip Code)

(630) 296-2223
(Registrant’s telephone number, including area code)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 Title of Each Class
 
Trading
Symbol 
 
Name of Each Exchange
on Which Registered 
         
Class A Common Stock, $0.0001 par value
 
ATIP
 
New York Stock Exchange
Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share
 
ATIP WS
 
OTC Market
  
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
 
On June 28,  2023, ATI Physical Therapy, Inc. (the “Company”) received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the Company no longer satisfies the continued listing standards set forth under Section 802.01B of the NYSE’s Listed Company Manual because the average market capitalization of the Company over a consecutive 30 trading-day period was less than $50 million and, at the same time, the Company’s last reported stockholders’ equity was less than $50 million (the “Market Capitalization Deficiency”). As of June 27, 2023, the 30 trading-day average market capitalization was approximately $41 million, and its last reported stockholders’ equity was approximately $20.5 million as of March 31, 2023. 
 
In accordance with applicable NYSE procedures, the Company has 45 days from receipt of the Notice to submit a business plan advising the NYSE of the definitive action(s) the Company has taken, or is taking, that would bring it into compliance with continued listing standards within 18 months of receipt of the Notice. The NYSE will review the plan and, within 45 days of its receipt, determine whether the Company has made a reasonable demonstration of an ability to conform to the relevant standards in the 18-month period. If the NYSE accepts the plan, the Company’s common stock will continue to be listed and traded on the NYSE during the 18-month period, subject to the Company’s compliance with the other continued listing standards of the NYSE and continued periodic review by the NYSE of the Company’s progress with respect to its plan.
 
The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on the NYSE during the applicable cure period, subject to the Company’s compliance with the other continued listing requirements of the NYSE. The Company’s common stock will continue to trade on the NYSE under the symbol “ATIP” with the designation of “.BC” to indicate the status of the shares as “below criteria.”
 
The Notice does not affect the Company’s reporting obligations with the Securities and Exchange Commission, and it does not conflict with or cause an event of default under any of the Company’s material debt or other agreements.
 
In addition, in its June 28, 2023 written notice, the NYSE advised the Company that it remains subject to the conditions set forth in the NYSE’s November 18, 2022 letter regarding noncompliance with the $1.00 over a 30 trading-day average price standard. The Company believes that it is in the process of regaining such compliance as a result of its previously announced reverse stock split effective June 15, 2023. 

Item 7.01
Regulation FD Disclosure
 
As required under the NYSE rules, the Company issued a press release on July 3, 2023, announcing that it had received the Notice from the NYSE described in Item 3.01. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
 
The information contained in, or incorporated into, this Item 7.01 of this Report, including Exhibit 99.1 attached hereto, is furnished under Item 7.01 of Form 8-K and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act regardless of any general incorporation language in such filings.
 
This Report shall not be deemed an admission as to the materiality of any information in this Report that is being disclosed pursuant to Regulation FD.

Item 9.01
Financial Statements and Exhibits
 
(a) Not applicable.
 
(b) Not applicable.
 
(c) Not applicable.
 
(d) Exhibits.
 
The exhibits required by this item are set forth on the Exhibit Index attached hereto.

 Exhibit
 Number
   
 Press Release dated on July 3, 2023
   
104
 Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: July 3, 2023
ATI Physical Therapy, Inc.
     
 
By:
/s/ Joseph Jordan
 
Name:
Joseph Jordan
 
Title:
Chief Financial Officer
 



Exhibit 99.1
 
 
 ATI Physical Therapy Receives NYSE Non-Compliance Letter
Regarding Market Capitalization Requirements

BOLINGBROOK, IL – JULY 3, 2023 – ATI Physical Therapy, Inc. (“ATI” or the “Company”) (NYSE: ATIP), a nationally recognized outpatient physical therapy provider in the United States, today announced that on June 28, 2023, the Company received a written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the Company no longer satisfies the continued listing standards set forth under Section 802.01B of the NYSE’s Listed Company Manual. The notice cited that the Company’s average market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, the Company’s last reported stockholders’ equity was less than $50 million. As of June 27, 2023, the 30 trading-day average market capitalization was approximately $41 million, and its last reported stockholders’ equity was approximately $20.5 million as of March 31, 2023.
 
According to NYSE procedures, the Company has 45 days from the date the Notice was received to submit a business plan advising the NYSE of the definitive action(s) the Company has taken, or is taking, to bring it into compliance within 18 months of receipt of the Notice. Within 45 days of its receipt, the NYSE will review the plan and determine whether the Company has made a reasonable demonstration to conform to the compliance requirements within the 18-month period.
 
Pending NYSE acceptance of the plan, the Company’s common stock will continue to be listed and traded on the NYSE during the 18-month period. Continued listing is also subject to the Company’s compliance with other applicable NYSE requirements and to periodic NYSE review of the Company’s progress toward achieving the previously submitted plan.
 
In the interim, the Company’s common stock will continue to trade on the NYSE under the symbol “ATIP” with the designation of “.BC” to indicate the status of the shares as “below criteria,” but is otherwise not immediately impacted by the Notice.
 
The Notice also does not affect Securities and Exchange Commission reporting obligations by the Company, nor does it conflict with or prompt default under any of the Company’s material debt or other agreements.

In addition, in its June 28, 2023 written notice, the NYSE advised the Company that it remains subject to the conditions set forth in the NYSE’s November 18, 2022 letter regarding noncompliance with the $1.00 over a 30 trading-day average price standard. The Company believes that it is in the process of regaining such compliance as a result of its previously announced reverse stock split effective June 15, 2023.


ABOUT ATI PHYSICAL THERAPY
 
At ATI Physical Therapy, we are passionate about potential. Every day, we restore it in our patients and activate it in our team members in our more than 900 locations in 24 states. With outcomes from more than 3 million unique patient cases, ATI is making strides in the industry by setting quality standards designed to deliver predictable outcomes for our patients with musculoskeletal (MSK) issues. ATI's offerings span across a broad spectrum for MSK-related issues. From preventative services in the workplace and athletic training support to outpatient clinical services and online physical therapy via our online platform, CONNECT, a complete list of our service offerings can be found at ATIpt.com. ATI is based in Bolingbrook, Illinois.
 
Forward-Looking Statements
 
All statements other than statements of historical facts contained in this communication are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of the words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," "potential," "seem," "seek," "future," "outlook," "target" or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the impact of physical therapist attrition and ability to achieve and maintain clinical staffing levels and clinician productivity, anticipated visit and referral volumes and other factors on the Company's overall profitability, and estimates and forecasts of other financial and performance metrics and projections of market opportunity. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company.
 
These forward-looking statements are subject to a number of risks and uncertainties, including:
 

our liquidity position raises substantial doubt about our ability to continue as a going concern;

risks associated with liquidity and capital markets, including the Company's ability to generate sufficient cash flows, together with cash on hand, to run its business, cover liquidity and capital requirements and resolve substantial doubt about the Company's ability to continue as a going concern;

our ability to meet financial covenants as required by our 2022 Credit Agreement;

risks related to outstanding indebtedness and preferred stock, rising interest rates and potential increases in borrowing costs, compliance with associated covenants and provisions and the potential need to seek additional or alternative debt or capital financing in the future;

risks related to the Company's ability to access additional financing or alternative options when needed;

our dependence upon governmental and third-party private payors for reimbursement and that decreases in reimbursement rates, renegotiation or termination of payor contracts or unfavorable changes in payor, state and service mix may adversely affect our financial results;

federal and state governments' continued efforts to contain growth in Medicaid expenditures, which could adversely affect the Company's revenue and profitability;

payments that we receive from Medicare and Medicaid being subject to potential retroactive reduction;
 


changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification and/or enrollment status;

compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;

risks associated with public health crises, including COVID-19 (and any existing and future variants) and its direct and indirect impacts on the business, which could lead to a decline in visit volumes and referrals;

risks related to the impact on our workforce of mandatory COVID-19 vaccination of employees;

our inability to compete effectively in a competitive industry, subject to rapid technological change and cost inflation, including competition that could impact our effectiveness of strategies to improve patient referrals and our ability to identify, recruit and retain skilled physical therapists;

our inability to maintain high levels of service and patient satisfaction;

risks associated with the locations of our clinics, including the economies in which we operate, size and expected growth of our addressable markets, and the potential need to close clinics and incur closure costs;

our dependence upon the cultivation and maintenance of relationships with customers, suppliers, physicians and other referral sources;

the severity of climate change or the weather and natural disasters that can occur in the regions of the U.S. in which we operate, which could cause disruption to our business;

risks associated with future acquisitions, which may use significant resources, may be unsuccessful and could expose us to unforeseen liabilities;

failure of third-party vendors, including customer service, technical and IT support providers and other outsourced professional service providers to adequately address customers' requests and meet Company requirements;

risks associated with our reliance on IT infrastructure in critical areas of our operations including, but not limited to, cyber and other security threats;

a security breach of our IT systems or our third-party vendors' IT systems may subject us to potential legal action and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 or the Health Information Technology for Economic and Clinical Health Act;

maintaining clients for which we perform management and other services, as a breach or termination of those contractual arrangements by such clients could cause operating results to be less than expected;

our failure to maintain financial controls and processes over billing and collections or disputes with third-parties could have a significant negative impact on our financial condition and results of operations;

our operations are subject to extensive regulation and macroeconomic uncertainty;

our ability to meet revenue and earnings expectations;

risks associated with applicable state laws regarding fee-splitting and professional corporation laws;

inspections, reviews, audits and investigations under federal and state government programs and payor contracts that could have adverse findings that may negatively affect our business, including our results of operations, liquidity, financial condition and reputation;

changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis;
 


the outcome of any legal and regulatory matters, proceedings or investigations instituted against us or any of our directors or officers, and whether insurance coverage will be available and/or adequate to cover such matters or proceedings;

our facilities face competition for experienced physical therapists and other clinical providers that may increase labor costs and reduce profitability;

risks associated with our ability to attract and retain talented executives and employees amidst the impact of unfavorable labor market dynamics and wage inflation, including potential failure of steps being taken to reduce attrition of physical therapists and increase hiring of physical therapists;

risk resulting from the IPO Warrants, Earnout Shares and Vesting Shares being accounted for as liabilities;

further impairments of goodwill and other intangible assets, which represent a significant portion of our total assets, especially in view of the Company's recent market valuation;

our inability to remediate the material weaknesses in internal control over financial reporting related to income taxes and to maintain effective internal control over financial reporting;

costs related to operating as a public company; and

risks associated with our ability to regain and sustain compliance with the listing requirements of our securities on the New York Stock Exchange ("NYSE").
 
If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements.
 
Investors should also review those factors discussed in the Company's amended S-1 registration statement filed with the SEC on April 12, 2022 under the heading "Risk Factors," our Form 10-K for the fiscal year ended December 31, 2022, the S-3 registration statement and amendments thereto dated August 10, 2022 and other documents filed, or to be filed, by ATI with the SEC. New risk factors emerge from time to time and it is not possible to predict all such risk factors, nor can the Company assess the impact of all such risk factors on the business of the Company or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. Readers should not place undue reliance on forward-looking statements. The Company undertakes no obligations to publicly update or revise any forward-looking statements after the date they are made or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or otherwise, except as required by law.
 
In addition, statements of belief and similar statements reflect the beliefs and opinions of the Company on the relevant subject. These statements are based upon information available to the Company, as applicable, as of the date of this communication, and while the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and statements should not be read to indicate that the Company has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.
 

Category: Corporate Transactions
 
Contacts:
 
Investor Relations
Joanne Fong
SVP, Treasurer and Head of Investor Relations
ATI Physical Therapy
investors@atipt.com
630-296-2223 ext. 7131

Media
Genesa Garbarino
Garbo Communications
genesa@garbo.agency
424-499-7025

Rob Manker
Director of Customer Marketing & Public Relations
ATI Physical Therapy
warren.manker@atipt.com
630-296-2222 ext. 7432

 

v3.23.2
Document and Entity Information
Jun. 28, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 28, 2023
Entity File Number 001-39439
Entity Registrant Name ATI PHYSICAL THERAPY, INC.
Entity Central Index Key 0001815849
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 85-1408039
Entity Address, Address Line One 790 Remington Boulevard
Entity Address, City or Town Bolingbrook
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60440
City Area Code 630
Local Phone Number 296-2223
Title of 12(b) Security Class A Common Stock, $0.0001 par value
Trading Symbol ATIP
Security Exchange Name NYSE
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false

ATI Physical Therapy (NYSE:ATIP)
過去 株価チャート
から 11 2024 まで 12 2024 ATI Physical Therapyのチャートをもっと見るにはこちらをクリック
ATI Physical Therapy (NYSE:ATIP)
過去 株価チャート
から 12 2023 まで 12 2024 ATI Physical Therapyのチャートをもっと見るにはこちらをクリック